Literature DB >> 1309691

[Thrombosis prevention in outpatients with lower limb injuries].

P Kujath1, U Spannagel, W Habscheid, G Schindler, A Weckbach.   

Abstract

The antithrombotic effect of a low molecular weight heparin was examined in a prospective randomized trial of 204 outpatients (121 men, 83 women, mean age 34.7 [16-76] years) who required immobilization with a plaster cast because of injury to the lower limb. Subjects in group I (n = 99) received a daily subcutaneous injection (36 mg) of heparin fragment calcium throughout their period in plaster (mean of 15.6 [7-66] days), while group II subjects (n = 105, mean period in plaster 15.7 [7-41] days) acted as untreated controls. Thrombosis was diagnosed by compression sonography, and positive findings were confirmed by phlebography. Thrombosis occurred in 24 patients altogether, 6 in group I (6.1%) and 18 in group II (17.1%) (P less than 0.05). While patients with thromboses had a mean of 1.96 risk factors overall, those in group I had a mean of 2.6 risk factors. Patients without thrombosis had a mean of 1.24 risk factors. The rate of thrombosis was higher in patients with fractures (4 out of 27 in group I; 10 out of 35 in group II) than in those with ligament and soft-tissue injuries (2 out of 72 in group I; 8 out of 70 in group II). The severity of trauma is apparently an important thrombogenic factor.--General thrombo-prophylaxis seems advisable for surgical outpatients requiring immobilisation treatment with a plaster cast.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1309691     DOI: 10.1055/s-2008-1062272

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  9 in total

Review 1.  A guide to venous thromboembolism risk factor assessment.

Authors:  G D Motykie; L P Zebala; J A Caprini; C E Lee; J I Arcelus; J J Reyna; E B Cohen
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

Review 2.  [An update on thrombosis prophylaxis in orthopaedic and accident surgery].

Authors:  J Grifka; S Haas; L Hovy; W Knopp; H L Refior; M Schürmann; T Wirth
Journal:  Orthopade       Date:  2004-07       Impact factor: 1.087

Review 3.  [Heparin-induced thrombocytopenia type II (HIT II) : A medical-economic view].

Authors:  R Riedel; A Schmieder; A Koster; S Kim; G Baumgarten; J C Schewe
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-12-22       Impact factor: 0.840

4.  [Implementing ambulatory prevention of thrombosis with low molecular weight heparin in plaster immobilization of the lower extremity].

Authors:  H J Kock; K P Schmit-Neuerburg; J Hanke; A Terwort; G Rudofsky; H Hirche
Journal:  Unfallchirurgie       Date:  1994-12

Review 5.  Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-limb immobilization.

Authors:  Aniek Ag Zee; Kelly van Lieshout; Maaike van der Heide; Loes Janssen; Heinrich Mj Janzing
Journal:  Cochrane Database Syst Rev       Date:  2017-08-06

6.  [Promoting venous return in plaster cast by AV impulse system. A preclinical study].

Authors:  C Bulitta; H J Kock; J Hanke; K W Sievers; K P Schmit-Neuerburg
Journal:  Unfallchirurgie       Date:  1996-08

7.  Prevention of deep venous thrombosis in ambulatory or discharged orthopaedic patients. Actual management.

Authors:  J Schmidt; M H Hackenbroch
Journal:  Arch Orthop Trauma Surg       Date:  1995       Impact factor: 3.067

8.  Deep venous thrombosis following different isolated lower extremity fractures: what is known about prevalences, locations, risk factors and prophylaxis?

Authors:  S Decker; M J Weaver
Journal:  Eur J Trauma Emerg Surg       Date:  2013-02-21       Impact factor: 3.693

9.  Insufficient Evidence for Routine Use of Thromboprophylaxis in Ambulatory Patients with an Isolated Lower Leg Injury Requiring Immobilization: Results of a Meta-Analysis.

Authors:  Roderik Metz; Egbert-Jan M M Verleisdonk; Geert J M G van der Heijden
Journal:  Eur J Trauma Emerg Surg       Date:  2008-12-08       Impact factor: 3.693

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.